US EditionAgreement Reached on EU's New Pharma Legislation
The reform sets up to 11 years of market protection and introduces incentives for antibiotics and generics to improve access and innovation, officials said.
9 Articles
9 Articles
EU forges deal over major pharma legislative changes
The European Council and Parliament on Thursday said that they reached agreement on a new set of pharmaceutical industry reforms — the first in more than two decades. But an industry group argues the deal will not make the EU’s pharma sector more competitive.
People are expected to have faster and safe access to medicines, to be more generic immediately available after patenting and more innovative antibiotics for combating bacterial resistance.
The recent interim agreement on the reform of European pharmaceutical legislation, reached after months of negotiation between European institutions, has generated a common ground between the European People's Party (PPE) and the Socialists and Democrats (S&D). Both groups stress that the agreement places biomedical innovation and equitable access to treatment at the heart of the Union's health policy, as well as incentives to investigate rare d…
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
